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Background: Cardiac shock wave therapy (CSWT) improves cardiac function in patients with severe coronary artery
disease (CAD). We aimed to evaluate the clinical outcomes of a new CSWT treatment regimen.
Methods: The 55 patients with severe CAD were randomly divided into 3 treatment groups. The control group
(n = 14) received only medical therapy. In group A (n = 20), CSWT was performed 3 times within 3 months. In
group B (n = 21), patients underwent 3 CSWT sessions/week, and 9 treatment sessions were completed within
1 month. Primary outcome measurement was 6-minute walk test (6MWT). Other measurements were also evaluated.
Results: The 6MWT, CCS grading of angina, dosage of nitroglycerin, NYHA classification, and SAQ scores were
improved in group A and B compared to control group.
Conclusions: A CSWT protocol with 1 month treatment duration showed similar therapeutic efficacy compared to a
protocol of 3 months duration.
Clinical trial registry: We have registered on ClinicalTrials.gov, the protocol ID is CSWT IN CHINA.
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The most common treatments for coronary artery disease
(CAD) are medications combined with percutaneous cor-
onary intervention (PCI) and coronary artery bypass graft
surgery (CABG). While PCI and CABG are not without
risks, overall results are satisfactory in patients who are
suitable candidates. However, the prognosis for patients
with refractory angina who are not candidates for PCI or
CABG is poor as maximal medical therapy is ineffective in
a large portion of these patients [1,2].
Shock wave (SW) therapy has been used successfully
to treat renal calculi (lithotripsy) and for a number of
orthopedic disorders [3,4]. Recently, experiments have
shown that SWs with energy output at approximately* Correspondence: guotao20@hotmail.com
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reproduction in any medium, provided the or10 % of what is used for lithotripsy can promote neovas-
cularization of cardiac tissue [5,6]. Subsequent clinical
studies have shown that cardiac shock wave therapy
(CSWT) can significantly improve cardiac function in
patients with severe CAD and refractory angina who are
not candidates for PCI or CABG [7-15]. One study that
treated 24 patients with ischemic heart failure and a left
ventricular ejection fraction (LVEF) < 40 % with CSWT
demonstrated that the treatment significantly improved
the cardiac functions assayed [9].
Though the results of CSWT for treating ischemic
heart disease are encouraging, current protocol demands
a treatment duration of three months. A one month
protocol has not previously been developed, but a
shorter protocol would save time and cost, produce bet-
ter compliance, and might be a more suitable protocol
than a three month protocol in China. Thus, the pur-
pose of this prospective study was to evaluate the clinical
outcome of a 1 month treatment regime as compared to
the standard 3 month treatment regimen as well as totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This study was approved by the Institutional Review
Board and Ethics Committee of 1st Hospital of Kum-
ming Medical University, and all study subjects signed
informed consent for participation in the study and all
treatments performed. Subjects were patients who were
hospitalized at Department of Cardiology of our hospital
from December 2008 to December 2009. Patients were
eligible to be included in the study if they met any of the
following criteria: 1) Coronary angiography (CA) or
multi-slice CT coronary angiography (CTCA) suggestive
of moderate to severe coronary artery stenosis. 2)
Demonstrated cardiac infarction and > 50 % stenosis
after radioactive and sonographic examinations. 3) Chest
tightness, onset of shortness of breath, and poor exercise
tolerance after receiving formal drug treatment (with or
without stent or bypass graft). 4) Hospitalized more than
2 times within 1 year due to the aforementioned pro-
blems. 5) CCS angina grading higher than grade II, and
NYHA functional classification of I-III. 6) More than
1 month after acute myocardial infarction (AMI) and
more than 2 weeks after PCI surgery. A history of PCI
or CABG was not a contraindication for inclusion. All
patients included in the study were “no option” patients
and had coronary heart disease and an imaging examin-
ation that confirmed the presence of ischemic myocar-
dium. The diagnosis and treatment in all the patients
was in accordance with the related domestic and Euro-
pean guidelines developed in 2007 [16].
Patients were excluded from the study if they met any
of the following criteria. 1) AMI or CABG within the
4 weeks prior to the study. 2) History of heart trans-
plantation. 3) History of metal valve replacement sur-
gery. 4) Intracardiac thrombus. 5) LVEF < 30 % and
unstable hemodynamics. 6) Arrhythmia with a rate
< 40 bpm or > 120 bpm. 7) Skin ulceration or infection
in the treatment area. 8) Severe obstructive lung disease.
Grouping
Initially, consecutive patients who met the inclusion cri-
teria were randomly divided into the regimen A treat-
ment group and the regimen B treatment group. After
three months, the additional group, a control group, was
added and subsequent patients were randomly added to
the regimen A and B groups and the control group.
Patients in the three groups were enrolled by a physician
who was familiar with patients’ conditions, and that
physician drew lots to divide the patients into the differ-
ent groups. The experimental grouping was blinded to
both the physicians who were responsible for treatmentand follow-up and to the patients themselves. The ma-
jority of patients with coronary heart disease in this
study had severe symptoms so that they had a strong de-
sire to receive CSWT. Therefore, we pre-set a smaller
sample size for the control group and the sample size
for this group was limited to no more than 15 patients.
The control group did not receive CSWT. The treat-
ment protocol of group A followed the recommended
protocol developed by Tohoku University of Japan with
respect to the shockwave output and the number of
shots delivered to each spot and the protocol developed
by the University of Essen, Germany [10,11]. In group A,
a sequence of 1 week treatment followed by three weeks
rest was repeated 3 times. During each treatment week,
CSWT was performed on days 1, 3 and 5, one session
each day. The total duration of treatment was 3 months,
thus patients received a total of 9 CSWT treatment ses-
sions. In group B, a modified CSWT treatment schedule
was adopted. Patients underwent 3 CSWT sessions/
week, and the 9 treatment sessions were completed
within 1 month. During follow-up, if the patient exhib-
ited no observable lessening of myocardial ischemia, 1–4
treatment courses were repeated.
Examinations before treatment
Dobutamine stress echocardiography (DSE). Patients
underwent DSE after vascular lesions were identified by
CA and/or CTCA. The use of β-blockers, calcium
antagonists, and nitrates were stopped for at least
24 hours before testing. Continuous intravenous infusion
of dobutamine (5–10 μg/kg/min) was administered, and
if regional wall motion abnormalities (RWMA) could
not be induced by low-dose dobutamine the dose was
increased to 20–40 μg/kg/min. The wall motion score
index (WMSI) was used to assess the state of motion.
Amplitude of regional myocardial motion was the
range of motion measured using M-type echocardiog-
raphy (Figure 1A). This allows semiquantification of
myocardial motion which can be displayed as a standard
M mode image. Viable myocardial segments were
defined as the 2 adjacent abnormal segments with im-
provement in contraction during drug administration
(decrease ≥ 1 point) [17,18].
Tissue Doppler-based strain rate (SR) was used to
measure peak systolic (PS) SR under resting and load
conditions (Figure 1B) [19,20]. Strain rate measures the
rate of deformation of a tissue segment and is measured
in S−1. PSSR represents the maximal rate of deformation
in systole. Strain is obtained by integrating strain rate
over time and represents deformation of a tissue seg-
ment over time. Strain is expressed as the percent
change from the original dimension. Systolic strain
represents the magnitude of deformation between end
diastole used as a reference point and end systole. One
Figure 1 Imaging methods. (A) Amplitude of regional myocardial motion was the range of motion measured using M-type echocardiography.
(B) PSSR was the measurement of the peak systolic strain rate using tissue Doppler imaging.
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ment for all the patients during the entire follow-up
period. However, that author did not know the treat-
ment of each patient. Before this study, that author con-
ducted a preliminary study on the feasibility and
repeatability of PSSR measurement of all 16 segments of
the left ventricle and the results showed no statistically
significant difference (P > 0.05). Before CSWT treat-
ment, radionuclide imaging and stress echocardiography
were used to locate the ischemic segments in each pa-
tient. These segments might be the middle or the apical
segment of interventricular septum, or the lateral basal
segment. The PSSR was measured in the specific ische-
mic segments.
Resting and dobutamine stress myocardial perfusion
imaging (MPI)
In order to assess myocardial perfusion more accurately,
identify the target for CSWT, and evaluate the thera-
peutic effects during follow-up, MPI was performed after
vascular lesions were identified. The use of β-blockers,
calcium antagonists, and nitrates were stopped at least
24 hours before testing. A two-day method was adopted
for dobutamine load and resting technetium (TC-99 m)
methoxy isobutyl isonitrile (99mTc-MIBI) MPI. The pa-
tient was asked to consume a high-fat meal after injec-
tion of contrast medium on the first day. Intravenous
continuous infusion of dobutamine (20–40 μg/kg/min)
was performed 40 min after the contrast medium in the
biliary tract was excreted and it was required that the
target heart rate (220 - age) was reached. Resting scan
was performed 40 min after injection of contrast
medium on the second day. Target myocardium was
located and quantified according to the 17-segmentMyocardial Scoring and the 4-grade scoring system
recommended by American Society of Nuclear Cardi-
ology [21-23]. An increase of 1-point or more in MPI
compared to baseline under both basic and loaded con-
ditions was considered as the criterion for local myocar-
dial blood flow improvement.Six-minute walk test (6MWT)
A 20-meter quiet and spacious corridor was designated,
and the patients were asked to walk in the corridor at
the maximum speed. If the patient experienced fatigue,
dizziness, angina, or shortness of breath within 6 min,
the test was stopped.CSWT treatment and control group
CSWT was performed with the MODULITH SLC SW
therapy device (Storz Medical, Switzerland). In brief,
after performing a 12-lead ECG, an ultrasound probe
was used to locate the target myocardium based on the
results of preoperative testing. A water bag was lowered
until it touched the chest wall. Shock waves were applied
to the ischemic areas, and were triggered by the R-wave
of the ECG when the instrument was activated. The
shock wave energy was increased up 0.09 mJ/mm2 if the
patient did not experience discomfort such as chest pain.
Point-to-point combination treatment (8 extra shock
wave treatments around the ischemic area) with 200
pulses delivered to each point was given. Thus, there
were 1800 shock waves administered for each infarcted
segment.
The control group did not undergo CSWT. During the
12-month follow-up, periodic telephone inquiries, out-
patient follow-up, and hospitalization were used to
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regular 3-month, 6-month, and 12-month follow-ups.
In both A and B groups, if acute heart failure, unregu-
lated blood pressure, and frequent chest tightness oc-
curred, the treatment was supplemented by timely drug
reinforcement and interventional treatment.
Follow-up
Patients were followed-up at 3, 6, and 12 months after
completion of treatment. Physicians who performed the
follow-up examinations were not aware as to which
treatment the patients received or if they were in the
control group. Follow-up examinations included clinical
assessment using the CCS grading of angina, NYHA
functional classification, Seattle Angina Questionnaire
(SAQ) [24], 6MWT, and recording the nitroglycerin dos-
age (times/week). Morphological assessment included
measurements of the left ventricular end-diastolic diam-
eter (LVDd) (two-dimensional long axis view of the left
ventricle), left ventricular end-diastolic volume (EDV)
(Simpson method), left ventricular end-systolic volume
(ESV) (Simpson method), LVEF (Simpson method), re-
gional wall motion under resting and load conditions
(M-type measurement), PSSR under resting and load
conditions (quantitative analysis using tissue velocity im-
aging), MPI score under resting and load conditions
(semi-quantitative analysis using bulls-eye map).
Statistical analysis
Data were summarized as mean ± SD for continuous
data with a normal distribution, median with interquar-
tile range (IQR: Q1, Q3) for data not normally distribu-
ted, and as number (%) for categorical data. Differences
among groups were compared using one-way ANOVA
with a post-hoc Bonferroni adjustment for continuous
data or Kruskal-Wallis test for continuous data that were
not normally distributed; Pearson chi-square test or
Fisher's exact test was used for categorical data.
ANCOVA was applied for comparing the effect between
groups and within groups. Non-parametric methods,
Kruskal-Wallis and Mann–Whitney U tests, were used
for comparing differences among groups, and pair-wise
comparison and Wilcoxon sign-rank test were used for
comparing the differences within groups as data were
not normally distributed. McNemar’s test was also ap-
plied for identifying the rate of subjects with improve-
ment MPI within groups. The 6MWT was designated as
the primary endpoint, and the b value of the 6MWT as
estimated by the difference between baseline and the
12 month time point was 91.39 % for the control vs.
group A, 70.15 % for the control vs. group B, and
12.17 % for group A vs. group B. All statistical assess-
ments were two-tailed and a value of P < 0.05 was con-
sidered statistically significant. Statistical analyses wereperformed using SPSS 15.0 statistics software (SPSS Inc.,
Chicago, IL, USA).
Results
A total of 55 patients who met the inclusion criteria
were enrolled. Patient characteristics are summarized in
Table 1. The 55 patients were randomly divided into one
control group (n = 14) and two treatment groups: treat-
ment group A (n = 20) and group B (n = 21). The mean
age in the control group, group A, and group B was 67.9
± 7.8 years, 62.7 ± 12.0 years, and 64.1 ± 9.8 years, re-
spectively with no significant difference. The only signifi-
cant difference between the groups was disease history
(P = 0.006). In the control group, all patients completed
follow-up until 12 months. One patient experienced a
recurrent AMI at the 3-month follow-up and underwent
emergency PCI. In group A, 20 patients completed the
6-month follow-up and 19 completed the 12-month fol-
low-up. One patient died from malignant arrhythmias
which induced sudden cardiac arrest after the 6-month
follow-up and 1 patient underwent PCI after the 6-
month follow-up due to aggravated angina. In group B,
21 patients completed the 6-month follow-up and 10
patients completed the 12-month follow-up. One patient
underwent PCI after the 6-month follow-up due to
aggravated angina. Thus, 39 patients (19 in group A and
10 in group B) completed CSWT treatment and
12 months follow-up without heart failure, syncope, pal-
pitations, breathing difficulty, bleeding, embolism, or
shock.
There were no significant differences in myocardial
enzymes or indicators of liver and kidney function be-
tween groups A and B before CSWT, or after the third
and ninth treatment (P > 0.05). Premature ventricular
contractions (PVCs) occurred in 4 cases in group A and
2 cases in group B during CSWT, but these did not
affect blood pressure, heart rate, or oxygen saturation.
The PVCs did not occur again during the following
weeks of treatment. Three patients in group A experi-
enced chest pain during the treatment of the ventricular
septum and the apical segment, and it was relieved after
the shock wave energy was reduced to 0.075-0.06 mJ/
mm2. Those patients were then treated with the same
lower energy, and chest pain did not occur again.
Table 2 shows the comparison of CCS grade, SAQ
score, 6MWT, nitroglycerin dosage, and NYHA classifi-
cation of the groups 0, 3, 6, and 12 months after treat-
ment. Within-group comparisons (compared with
month 0) revealed the mean CCS was significantly
decreased in both groups A and B from month 3 to
month 12. In the control group, mean CCS was only sig-
nificantly decreased at month 6 as compared with
month 0. The mean SAQ score at month 6 and month
12 in group A and at months 3, 6, and 12 in group B
Table 1 Subject characteristics
Control group (n = 14) Group A (n = 20) Group B (n = 21) P
Age, years 67.9 ± 7.8 62.7 ± 12.0 64.1 ± 9.8 0.337
Sex, male (%) 12 (85.7) 18 (90) 17 (81) 0.882
BMI, kg/m2 24.0 ± 3.2 24.5 ± 2.8 23.4 ± 2.7 0.513
Disease history, years 3 (2, 5) 4 (2.0 , 7.8) 2 (1 , 2) 0.006*
Smokers 6 (42.9) 7 (35.0) 9 (42.9) 0.884
Underwent stenting 11 (78.6) 14 (70) 9 (42.9) 0.080
Comorbid conditions
Essential hypertension 10 (71.4) 13 (65.0) 16 (76.2) 0.708
Diabetes mellitus 4 (28.6) 7 (35.0) 4 (19.0) 0.553
Hyperlipidemia 6 (42.9) 4 (20.0) 4 (19.0) 0.259
COPD 1 (7.1) 0 (0) 0 (0) NA
Chronic renal failure 0 (0) 1 (5.0) 2 (9.5) NA
Atrial fibrillation 0 (0) 1 (5.0) 0 (0) NA
Ulcerative colitis 0 (0) 0 (0) 1 (4.8) NA
Condition 0.383
Stable angina pectoris 2 (14.3) 0 (0) 0 (0)
Old myocardial infarction 8 (57.1) 13 (65.0) 14 (66.7)
Unstable angina pectoris 4 (28.6) 7 (35.0) 7 (33.3)
Medical therapy
Anti-platelet agents 9 (64.3) 11 (55.0) 14 (66.7) 0.774
Aspirin 12 (85.7) 17 (85.0) 19 (90.5) 0.883
Angiotensin-converting enzyme inhibitors 7 (50.0) 7 (35.0) 8 (38.1) 0.732
Angiotensin receptor blocker 1 (7.1) 4 (20.0) 4 (19.0) 0.659
β-blockers 13 (92.9) 18 (90.0) 18 (85.7) 0.872
Calcium channel blockers 4 (28.6) 6 (30.0) 11 (52.4) 0.281
Statin 13 (92.9) 18 (90.0) 17 (81.0) 0.675
Nitrates 4 (28.6) 8 (40.0) 9 (42.9) 0.727
Diuretics 2 (14.3) 3 (15.0) 3 (14.3) 1.000
Oral hypoglycemic agents 3 (21.4) 2 (10.0) 3 (14.3) 0.648
Insulin 2 (14.3) 2 (10.0) 1 (4.8) 0.623
Patients who experienced re-infarction 1 (7.1) 0 (0) 0 (0) NA
Re-hospitalization 0.461
Once 4 (28.6) 2 (10) 2 (9.5)
Twice 1 (7.1) 1 (5) 1 (4.8)
Thrice 1 (7.1) 1 (5) 0 (0)
Mortality 0 (0) 1 (5.0) 0 (0) NA
Location of ischemic target area
Ventricular septum 11 (78.6) 11 (55.0) 12 (57.1) 0.365
Anterior wall 2 (14.3) 4 (20) 4 (19) 1.000
Inferior wall 5 (35.7) 11 (55.0) 14 (66.7) 0.194
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Table 1 Subject characteristics (Continued)
Posterior wall 1 (7.1) 3 (15.0) 3 (14.3) 0.771
Lateral wall 2 (14.2) 3 (15.0) 0 (0) 0.161
Number of shock wave treatment (9 times/per treatment course) NA 2 (1, 2.8) 2 (1, 2.5) 0.904
Duration of treatment interval, month NA 5 (4, 6.5) 4 (4, 5.5) 0.231
COPD: chronic obstructive pulmonary disease.
Data are presented as mean ± standard deviation, number (%), or median (IRQ) as described in the statistical analysis methods.
*P < 0.05, indicated significant difference was identified among control group, group A, and group B.
NA, not assessed.
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The mean 6MWT result at month 3, 6, and 12 in group
A and at months 3 and 6 in group B was significantly
increased as compared with month 0. We also per-
formed a treadmill walk test for some, but not all, of the
patients (Additional file 1: Table S1.) This test showed a
significant increase in exercise tolerance in both CSWTTable 2 Comparison of CCS, SAQ, 6MWT, nitroglycerin dosag
Control group (14) G
6MWT, meters
0 month 363.86 ± 150.92 3
3 month 322.07 ± 150.07 4
6 month 325.93 ± 157.32 4
12 month 348.43 ± 132.06 4
CCS grading of angina
0 month 2 (2.0, 3.0) 2
3 month 2 (2.0, 2.3) 1
6 month 2 (1.0, 2.3)} 1
12 month 2 (1.0, 3.0) 1
NYHA classification
0 month 2 (1, 3) 1
3 month 1 (1, 3) 1
6 month 1 (1, 2.3) 1
12 month 1 (1, 2.3) 1
SAQ score
0 month 63.21 ± 11.89 6
3 month 63.86 ± 13.27 6
6 month 60.14 ± 12.82 7
12 month 59.21 ± 15.66 7
Nitroglycerin (times/week)
0 month 1 (0, 4) 1
3 month 1 (0, 4) 0
6 month 0 (0, 2) 0
12 month# 1 (0, 3) 0
Data were presented as mean ± standard deviation, number (%), or median (IRQ) a
#One patient in group A and 11 patients in group B had missing data of nitroglycer
*P < 0.05, indicates significant difference among control group, group A, and group
a,bP < 0.0167 (0.05/3), indicates significant difference was identified when compared
}P < 0.05, indicates significant difference was identified when compared with montgroups, but not in the control group. The median
NYHA classification score at month 3, 6, and 12 was sig-
nificantly decreased as compared to month 0 in both
group A and B (all, P < 0.05, Table 2).
Figure 2 shows a comparison of the amplitude of re-
gional myocardial motion and PSSR between- and
within-groups. The baseline PSSR at month 12, PSSRe, and NYHA classification
roup A (n = 20) Group B (n = 21) P
44.25 ± 106.44 329.43 ± 134.71 0.617
22.20 ± 77.30} 385.43 ± 78.62} 0.073
34.25 ± 99.70} 405.33 ± 104.36} 0.296
77.95 ± 105.34a} 452.00 ± 117.47a 0.020*
(1, 2) 3 (2, 3)b 0.045*
(1, 1)a} 2 (1, 2)} <0.001*
(1, 1)a} 2 (1, 2)} 0.016*
(1, 1)a} 1 (1, 2)a} <0.001*
.5 (1, 3) 2 (1, 2.5) 0.822
(1, 2)} 1 (1, 1)} 0.138
(1, 1)} 1 (1, 1)} 0.081
(1, 1)} 1 (1, 1)a} 0.018*
4.90 ± 11.72 67.71 ± 13.05 0.549
9.50 ± 10.28 76.38 ± 13.20a} 0.015*
5.00 ± 10.45a} 76.14 ± 12.28a} <0.001*
9.63 ± 9.87a} 82.70 ± 10.16a} <0.001*
(0, 2) 2 (0, 3) 0.589
(0, 1) 0 (0, 2) 0.151
(0, 1) 0 (0, 1) 0.597
(0, 0)a 0 (0, 0)a 0.023*
s described in the statistical analysis methods.
in dosage at month 12.
B.
with acontrol group and bgroup A.
h 0 of the corresponding group.
Figure 2 Comparison of amplitude of regional myocardial motion at baseline (A-1) and after dobutamine loading (A-2), and PSSR
score at baseline (B-1) and after dobutamine loading (B-2). Data were presented as mean ± standard deviation as described in the statistical
analysis methods. Twelve patients in group B had a missing record PSSR at baseline in 12 months. *P < 0.05, indicated significant difference was
identified among control group, group A, and group B. }P < 0.05, indicated there was significant difference as comparing with time = 0 months
for a given baseline or after load conditions in the corresponding group.
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month 0 were significantly different between the three
groups. Within-group comparisons showed that for both
group A and B, the amplitude of regional myocardial
motion at month 3, 6, and 12 were all significantly
higher than month 0 in both the baseline and the loaded
conditions. For PSSR, the between-group comparisons
showed significant differences at month 6 and 12 in both
the baseline and loaded conditions.
Results of MPI scores that measured the improvement
of individual myocardial segments are shown in Figure 3.
Successful treatment was defined as an increase of 1
point or more compared to month 0 in both baseline
and loaded conditions. Although there is an increase in
percentage of myocardia successfully treated in group A,
the difference is not significant between group A and B.
Discussion
In the current study, following 12 months of observa-
tion, the CSWT treatments using two different regimens
both provided satisfactory results that improved myocar-
dial function comparing to pretreatment (month 0) and
to the control group. These results suggest a more fre-
quent treatment regimen (one month) can also provide
equivalent therapeutic efficacy compared to the regimen
of less frequent CSWT treatment (three months).PSSR, the technique used in this study, has higher
temporal and spatial resolution than M type imaging
[25,26]. Voight’s study showed that the peak systolic
strain rate (PSSR) in the long-axis view decreased with
the deterioration of the wall motion and that its sensitiv-
ity for determining myocardial ischemia was 86 % and
its specificity 90 % in the dobutamine stress test [25]
However, compared with the latest 2D-strain testing,
PSSR is affected by the angle and can only measure the
radial strain in the apical four-chamber and apical two-
chamber view. It cannot measure the strain in the short-
axis view. The present study selected PSSR to assess the
local cardiac function because it was the earliest and
most mature method available at the beginning of the
study. Our research team members have used it for
many years, therefore systematic errors can be reduced.
Another reason for using PSSR is that we use GE VV7
instrument in our lab, and it has complete TDI and
strain rate imaging software. The 2D-strain requires the
SIMENS Sequia 512 instrument, and that instrument
was not introduced until the late stage of this study.
Therefore, in order to keep the consistency of results,
we did not change the measurement indices.
Two prior studies were conducted by our research
team. In the first, CCS grading of angina and dosage of
nitrate esters were significantly reduced in 9 patients
Figure 3 Number of ischemic segments with increased baseline
and post-dobutamine loading MPI scores. Results were presented
as bar chart as for the percentage of (A) increased from baseline
value at 3 month and 6 month for each group, (B) increased from
baseline dobutamine loading value at 3 month and 6 month for
each group, and (C) increased from baseline value and baseline
dobutamine loading value at 3 month and 6 month for each group.
*P < 0.05, indicates significant difference among groups through
Fisher’s exact test. aP < 0.0167 (0.05/3) indicates significant difference
between group A and B through Chi-square test. } P < 0.05 indicates
significant difference within groups (0 to 6 months vs. 0 to
3 months) through McNemar’s test.
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tolic function was improved significantly 1 month after
treatment [12]. In the second, 25 patients had 9 CSWT
treatments and two imaging methods were used, PSSR
and MPI. In this study, the CCS grading of angina and
dosage of nitrate esters, 6MWT, NYHA functional clas-
sification, and SAQ score were significantly improved
and the PSSR after load and resting MPI were also sig-
nificantly improved at the one month follow-up [13].
Other reports have also been encouraging. Fukumoto
et al. [11] treated 9 patients with end-stage CAD who
were not candidates for CABG or PCI, and at 12 months
of follow-up reported that CSWT had significantly
reduced nitroglycerine use (from 5.4 ± 2.5 to 0.3 ± 0.3
times/week), improved CCS functional class score (from
2.7 ± 0.2 to 1.8 ± 0.2), and improved myocardial perfu-
sion as assessed by dipyridamole stress thallium scintig-
raphy (severity score, 25.2 ± 7.2 % improvement; extent
score, 23.3 ± 9.0 % improvement). Khattab et al.[10]
treated 10 patients with refractory AP who were CCS
class III or IV despite maximal medical therapy with
CSWT and reported that the mean CCS class decreased
from 3.3 ± 0.5 at baseline to 1.0 ± 13 at follow-up and
the mean summed stress score decreased from 8.3 ± 2.2
at baseline to 3.0 ± 3.1 at follow-up.
A shock wave propagates though water as a spike <
1 μs in duration with an amplitude up to 100 MPa, that
is followed by a lower amplitude tensile portion lasting
several microseconds [7]. Early studies with animal mod-
els of angina pectoris and AMI indicated that CSWT at
approximately 10 % of the energy used for lithotripsy
could improve left ventricular wall motion, LVEF, LV
end-diastolic volume, and regional blood flow and num-
ber of capillaries in the border zone (MI) [7]. However,
the molecular mechanism by which shock waves pro-
mote neovascularization and improvement of cardiac
function has not been determined.
Shock waves have been reported to activate Ras,
stimulate NO synthesis, produce anti-inflammatory
effects by affecting the expression of chemokines and
matrix metalloproteases, and upregulate VEFG and the
VEGF receptor (Flt-1) [5,27-31]. How these effects lead
to cardiac changes and improvement of cardiac function
are not clear; however, it is possible that shock waves in-
crease the incorporation of circulating endothelial pro-
genitor cells (EPCs) by up-regulating the expression of
stromal-derived factor 1 (SDF-1), which is necessary for
the recruitment and incorporation of EPCs, in ischemic
myocardium [7,32].
In our study, the one month treatment had the same
efficacy as the 3 month treatment at the 12 month fol-
low-up. These results are exciting, but the mechanism
by which a shorter term, more frequent treatment pro-
duces the same effect as a longer term, less frequent
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ism might be related to the cellular and molecular
mechanisms of blood vessel formation [33-35]. In other
words, when repeated shock wave stimulations are given
within 1 month, the resulting succession of shear force
effects will produce a waterfall phenomenon, and a large
number of neovascular networks will form in a short
period of time, ultimately promoting the establishment
of collateral circulation in the ischemic area.
Limitations of the study are that we only used our sec-
ond objective test of working capacity on a partial sam-
ple of the patient population. Also, because the patients
in group B were admitted to the study later than the
patients in group A, only 11 of the 21 patients in group
B had been followed up at the time the paper was
written.
Conclusions
In summary, our results showed that CSWT can im-
prove clinical symptoms and morphological and func-
tional indices in patients with complex CAD. A CSWT
treatment regimen of one month duration provided
similar therapeutic efficacy compared to a regimen with
three months duration. CSWT is proven effective and
useful for patients excluded from CABG and PCI ther-
apies and patients whose medication treatments are no
longer effective.
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